DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/ttfrkr/rubella) has announced the addition of the "Rubella - Pipeline Review, H2 2013" report to their offering.
'Rubella - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rubella, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rubella.
- A snapshot of the global therapeutic scenario for Rubella.
- A review of the Rubella products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Rubella pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Key Topics Covered:
Tables & Figures
Rubella - Pipeline Products Glance
Rubella - Companies Involved in Therapeutics Development
- GlaxoSmithKline plc
- Zydus Cadila Healthcare Limited
- Cadila Pharmaceuticals Ltd.
- Sinovac Biotech Ltd.
- Beijing Tiantan Biological Products Co., Ltd.
Rubella - Therapeutics Assessment
measles, mumps and rubella vaccine (live)
Live Rubella Vaccine
Measles and Rubella Vaccine
Vaccine For Live Measles, Mumps and Rubella
MMR + Varicella Vaccine
Rubella - Recent Pipeline Updates
Featured News & Press Releases
For more information visit http://www.researchandmarkets.com/research/ttfrkr/rubella